IN-DEPTH TRENDING ONCOLOGY EXPERIENCE

Committed To The Quest To Cure Cancer

IN-DEPTH TRENDING ONCOLOGY EXPERIENCE

In the past 5 years:

  • 180+ Clinical Trials
  • 35+ Indications
  • 14,200 Patients
  • 2,900 Sites

In the past 5 years alone, Synteract has managed 180+ clinical oncology trials, with the greatest percentage of those in complex and challenging areas such as pathway-targeted therapies, chemotherapy, and immunotherapy, as well as cell-based therapies and gene therapies.

Our 30-year, in-depth oncology trial knowledge spans the entire clinical process, from design and execution of proof-of-concept trials to submissions and regulatory approval.

  • We were the first CRO that began working in the innovative immunotherapy clinical development area over 10 years ago.
  • We have first-hand experience and specialized expertise in precision medicine trials matched to specific patient biomarkers and personalized treatments customized to the individual.

Every project is unique, and we treat it accordingly. With greater than 85 percent of our project management team having oncology experience, our caring, highly skilled experts are personally driven to develop better therapies for patients.

In the highly dynamic and evolving cancer research landscape, we bring our longstanding oncology acumen to bear. We have performed nearly 500 Phase I-IV oncology projects over our history, including hematological malignancies and other cancer types. We have developed a particular depth of experience in early phase oncology research for drugs designed to treat blood, breast, lung, gastrointestinal, skin, and numerous other cancers. The strong relationships we’ve developed with oncology investigative sites support your mission to advance treatments in this critical area of research.

Oncology Experience:

Oncology Pie Chart
  • A - Pathway-targeted therapies: 49%
  • B - Other areas of oncology: 22%
  • C - Immunotherapy: 16%
  • D - Chemotherapy: 4%
  • E - Cells and gene therapies: 3.5%
  • F - Dermatology: 7%
  • G - Diagnostic: 3%
  • H - Hormonotherapy: 2%
x

Contact Synteract

Tell us how to stay in touch with you:

*Required